Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q1 2009
Executive Summary
Highlights from the Q1 2009 review of medical device and in vitro diagnostics/research dealmaking. Device financing activity remained down bringing in only $522 million--the majority invested through VCs, mostly via late-stage venture rounds--not much change from the previous quarter, but a significant drop from Q1 2008, which saw $920 million. Device M&A brought in $4.4 billion, double the previous quarter, but most of Q1's money came from Abbott's $2.86 billion purchase of Advanced Medical Optics. Four other transactions topped the $200 million mark, including three deals by device giant Medtronic, which grabbed cardio companies CoreValve, Ventor Technologies, and Ablation Frontiers. There was also a decline in in vitro diagnostics and research fund-raising with 2009's opening quarter only seeing about half the dollars of Q4 2008.
You may also be interested in...
Sequenom's Failure Highlights an Underappreciated Risk of Biotech Investing
Sequenom's late April announcement that the R&D data associated with its soon-to-be-launched test for Down syndrome "was mishandled by individuals in our company" sent a cold shiver throughout the biotech investment community. As if the biotech investment model wasn't risky enough, the firm had to go and introduce a new one.
Cataract and Refractive Surgery: Hoping For a Rebound
April's annual meeting of the American Society of Cataract and Refractive Surgery took place against of the darkest market backdrops in memory. The mood at ASCRS was not all gloom and doom, however. Cataract and refractive surgery technology continues to advance and a number of new product were introduced at the meeting.
Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys
Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion